Literature DB >> 20132124

Indicators of buprenorphine and methadone use and abuse: what do we know?

Jane Carlisle Maxwell1, Elinore F McCance-Katz.   

Abstract

Abuse of prescription opioids is a growing problem. The number of methadone pain pills distributed now exceeds liquid methadone used in opioid treatment, and the increases in buprenorphine indicators provide evidence of the need to monitor and intervene to decrease the abuse of this drug. The need for additional and improved data to track trends is discussed, along with findings as to the characteristics of the users and combinations of drugs. Data on toxicities related to methadone or buprenorphine, particularly in combination with other prescribed drugs, are presented and clinical implications and considerations are offered. These findings underscore the need for physicians to be aware of potential toxicities and to educate their patients regarding these issues.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20132124      PMCID: PMC3723402          DOI: 10.1111/j.1521-0391.2009.00008.x

Source DB:  PubMed          Journal:  Am J Addict        ISSN: 1055-0496


  29 in total

1.  Injecting misuse of buprenorphine among French drug users.

Authors:  Y Obadia; V Perrin; I Feroni; D Vlahov; J P Moatti
Journal:  Addiction       Date:  2001-02       Impact factor: 6.526

2.  Diazepam and methadone blood levels following concurrent administration of diazepam and methadone.

Authors:  K L Preston; R R Griffiths; E J Cone; W D Darwin; C W Gorodetzky
Journal:  Drug Alcohol Depend       Date:  1986-10       Impact factor: 4.492

Review 3.  New insights into the role of the GABA(A)-benzodiazepine receptor in psychiatric disorder.

Authors:  D J Nutt; A L Malizia
Journal:  Br J Psychiatry       Date:  2001-11       Impact factor: 9.319

4.  Clinical pharmacology of buprenorphine: ceiling effects at high doses.

Authors:  S L Walsh; K L Preston; M L Stitzer; E J Cone; G E Bigelow
Journal:  Clin Pharmacol Ther       Date:  1994-05       Impact factor: 6.875

Review 5.  Methadone--metabolism, pharmacokinetics and interactions.

Authors:  Anna Ferrari; Ciro Pio Rosario Coccia; Alfio Bertolini; Emilio Sternieri
Journal:  Pharmacol Res       Date:  2004-12       Impact factor: 7.658

6.  Buprenorphine prescription by general practitioners in a French region.

Authors:  X Thirion; V Lapierre; J Micallef; E Ronflé; A Masut; V Pradel; C Coudert; J C Mabriez; J L Sanmarco
Journal:  Drug Alcohol Depend       Date:  2002-01-01       Impact factor: 4.492

Review 7.  Benzodiazepines, methadone and buprenorphine: interactions and clinical management.

Authors:  Nicholas Lintzeris; Suzanne Nielsen
Journal:  Am J Addict       Date:  2010 Jan-Feb

8.  Benzodiazepine and sedative use/abuse by methadone maintenance clients.

Authors:  M Y Iguchi; L Handelsman; W K Bickel; R R Griffiths
Journal:  Drug Alcohol Depend       Date:  1993-05       Impact factor: 4.492

Review 9.  Buprenorphine: a primer for emergency physicians.

Authors:  Karl A Sporer
Journal:  Ann Emerg Med       Date:  2004-05       Impact factor: 5.721

10.  Dose-related effects of methadone on QT prolongation in a series of patients with torsade de pointes.

Authors:  Mori J Krantz; Ilana B Kutinsky; Alastair D Robertson; Philip S Mehler
Journal:  Pharmacotherapy       Date:  2003-06       Impact factor: 4.705

View more
  13 in total

1.  Oligodendrocyte responses to buprenorphine uncover novel and opposing roles of μ-opioid- and nociceptin/orphanin FQ receptors in cell development: implications for drug addiction treatment during pregnancy.

Authors:  Andrew C Eschenroeder; Allison A Vestal-Laborde; Emilse S Sanchez; Susan E Robinson; Carmen Sato-Bigbee
Journal:  Glia       Date:  2011-10-14       Impact factor: 7.452

2.  Abuse potential of intranasal buprenorphine versus buprenorphine/naloxone in buprenorphine-maintained heroin users.

Authors:  Jermaine D Jones; Maria A Sullivan; Suzanne K Vosburg; Jeanne M Manubay; Shanthi Mogali; Verena Metz; Sandra D Comer
Journal:  Addict Biol       Date:  2014-07-25       Impact factor: 4.280

3.  Buprenorphine maintenance therapy in opioid-addicted health care professionals returning to clinical practice: a hidden controversy.

Authors:  Heather Hamza; Ethan O Bryson
Journal:  Mayo Clin Proc       Date:  2012-03       Impact factor: 7.616

4.  Illicit use of buprenorphine in a community sample of young adult non-medical users of pharmaceutical opioids.

Authors:  Raminta Daniulaityte; Russel Falck; Robert G Carlson
Journal:  Drug Alcohol Depend       Date:  2011-10-28       Impact factor: 4.492

5.  Management of opioid use disorders: a national clinical practice guideline.

Authors:  Julie Bruneau; Keith Ahamad; Marie-Ève Goyer; Ginette Poulin; Peter Selby; Benedikt Fischer; T Cameron Wild; Evan Wood
Journal:  CMAJ       Date:  2018-03-05       Impact factor: 8.262

6.  The reinforcing and subjective effects of intravenous and intranasal buprenorphine in heroin users.

Authors:  Jermaine D Jones; Gabriela Madera; Sandra D Comer
Journal:  Pharmacol Biochem Behav       Date:  2014-05-02       Impact factor: 3.533

7.  The pharmacodynamic and pharmacokinetic profile of intranasal crushed buprenorphine and buprenorphine/naloxone tablets in opioid abusers.

Authors:  Lisa S Middleton; Paul A Nuzzo; Michelle R Lofwall; David E Moody; Sharon L Walsh
Journal:  Addiction       Date:  2011-05-03       Impact factor: 6.526

8.  Pharmacokinetics of Sublingual Buprenorphine and Naloxone in Subjects with Mild to Severe Hepatic Impairment (Child-Pugh Classes A, B, and C), in Hepatitis C Virus-Seropositive Subjects, and in Healthy Volunteers.

Authors:  Azmi F Nasser; Christian Heidbreder; Yongzhen Liu; Paul J Fudala
Journal:  Clin Pharmacokinet       Date:  2015-08       Impact factor: 6.447

9.  Supporting individuals using medications for opioid use disorder in recovery residences: challenges and opportunities for addressing the opioid epidemic.

Authors:  Jennifer Miles; Jason Howell; Dave Sheridan; George Braucht; Amy Mericle
Journal:  Am J Drug Alcohol Abuse       Date:  2020-02-24       Impact factor: 3.829

Review 10.  Treatment of Chronic Hepatitis C in Patients Receiving Opioid Agonist Therapy: A Review of Best Practice.

Authors:  Brianna L Norton; Matthew J Akiyama; Philippe J Zamor; Alain H Litwin
Journal:  Infect Dis Clin North Am       Date:  2018-06       Impact factor: 5.982

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.